Please login to the form below

Not currently logged in
Email:
Password:

CRS-207

This page shows the latest CRS-207 news and features for those working in and with pharma, biotech and healthcare.

Aduro pancreatic cancer vaccine trial disappoints

Aduro pancreatic cancer vaccine trial disappoints

The immunotherapy combines CRS-207 - a drug that promotes the expression of the tumour-associated antigen mesothelin - with an immune-boosting GVAX cell line, and is Aduro's lead product candidate. ... The regimen was unable to improve overall survival

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics